Esindajate nimetamine

Saatja: Esindus EL juures üldaadress </O=ESTONIAN MINISTRY OF FOREIGN AFFAIRS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=USERF5F556D8> Saaja: Tiiu Noobel Teema: FW: Estonia - 2026-06-08 - Nomination invitation for PDCO member and alternate From: Barbero Martina <[email protected]> Sent: Monday, June 8, 2026 11:19 AM To: Esindus EL juures üldaadress <[email protected]> Cc: Kiisk Katrin <[email protected]>; Kompus Mairi <[email protected]>; Jenas Kärolin <[email protected]>; PDCO Secretariat <[email protected]>; Nominations <[email protected]>; Lass Jana <[email protected]>; Saare Liisa <[email protected]> Subject: Estonia - 2026-06-08 - Nomination invitation for PDCO member and alternate Your Excellency, Please find attached a letter signed by the European Medicines Agency's Executive Director requesting the nomination of a representative to the Agency's Scientific Committees. The letter is accompanied by: • Annex B • Committee composition and expertise You are kindly invited to address nominations to the European Medicines Agency’s Executive Director at [email protected] <mailto:[email protected]> (with copy to [email protected] <mailto:[email protected]> ). Please do not hesitate to contact me should you have any questions regarding this request for nomination. For the information of the National Competent Authority in cc of this email The nominee, if not registered in Experts Management Tool, will be required to register at: https://experts.ema.europa.eu/ <https://experts.ema.europa.eu/> • Registering in the Experts Management Tool, experts will be required to provide: Contact details and areas of expertise, Declaration of Interests, Curriculum Vitae. This should be completed with as much detail as possible. • Instructions on how to register in the Experts Management Tool can be found in this user manual (link <https://experts.ema.europa.eu/csp?id=kb_article_view&sysparm_article=KB0010555> ). The EMA policy and guidance document can be found on the EMA website: • European Medicines Agency policy on the handling of competing interests of scientific committees’ members and experts (link <https://www.ema.europa.eu/documents/other/policy-44-european-medicines-agency-policy-handling-competing-interests-scientific-committees_en.pdf> ) • Procedural guidance on inclusion of declared interests in the European Medicines Agency’s declaration of interests (for scientific committees’ members and experts) (link <https://www.ema.europa.eu/documents/regulatory-procedural-guideline/procedural-guidance-inclusion-declared-interests-european-medicines-agencys-electronic-declaration_en.pdf> ) Nominees will be subject to a pre-screening of any declared competing interest in line with the Agency's policy on handling of competing interests. In case of a negative outcome, the Agency will provide feedback of this screening to the nominating authority for subsequent consideration. I would like to emphasize the importance of a timely nomination of a committee member to ensure the continuous representation of your Member State in the Committee. To avoid a vacant committee member position when an alternate position is already filled, you may consider nominating the alternate (temporarily) as member. Please also inform me if you intend to keep the position temporarily vacant. If no nomination is received, the position will be considered temporarily vacant until a nomination is received. Sincerely yours, Martina Barbero Experts and Declarations of Interests Management Meeting Secretariat Office Committees and Quality Assurance Department European Medicines Agency <https://www.ema.europa.eu/> Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands Tel. +31887816550 [email protected] <mailto:[email protected]> | www.ema.europa.eu <https://www.ema.europa.eu/en> | For directions, see How to find us <https://www.ema.europa.eu/en/about-us/contact/how-find-us> Follow us: <https://www.youtube.com/user/emainfo> <https://www.linkedin.com/company/european-medicines-agency/> <https://bsky.app/profile/ema-eu.bsky.social> <https://www.instagram.com/onehealth_eu/> This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this e-mail, or any disclosure or copying of its contents, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately. Classified as internal/staff & contractors by the European Medicines Agency Classified as confidential by the European Medicines Agency HE the Ambassador Permanent Representation of Estonia Rue Guimard 11–13 B-1040 Bruxelles BELGIUM 8 June 2026 EMA/PDCO/133176/2026 Executive Director Your Excellency, Subject: Nomination of representatives in the Paediatric Committee (PDCO) of the European Medicines Agency In accordance with Regulation (EC) No 726/2004, members and alternates of the European Medicines Agency’s Management Board and scientific committees are nominated for a three-year mandate by EU member states and EEA-EFTA countries. The three-year mandate of the representatives listed below is due to expire. I, therefore, invite you to nominate representatives for a new three-year mandate starting from the date indicated below. In case you are nominating new representatives and a different start date for the mandate is envisaged, please inform me accordingly. • Jana Lass Member 19 October 2026 • Liisa Saare Alternate 19 October 2026 I would like to emphasize the importance of a timely nomination of a committee member to ensure the continuous representation of your Member State in the Committee. To avoid a vacant committee member position when an alternate position is already filled, you may consider nominating the alternate (temporarily) as member. Please also inform me if you intend to keep the position temporarily vacant. If no nomination is received, the position will be considered temporarily vacant until a nomination is received. In making your nominations, please note that the Agency’s Management Board has determined that members of scientific committees should meet conditions concerning their declarations of interests as described in the Policy on the handling of competing interests of scientific committees’ members and experts. This policy can be found on the EMA website. I would like to draw your attention to the attached Annex B, which lists the recommended criteria for experience and expertise of the Committee members and alternates for consideration when nominating a new representative. As agreed with the network of the Heads of Medicines Agencies in order to address the increasing complexity in scientific developments related to the Committee’s activities, the current expertise of the Committee and the expertise required for upcoming procedures are monitored. It would be appreciated if the following specific areas of expertise that were identified as desirable for the current and Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2026. Reproduction is authorised provided the source is acknowledged. upcoming work of the Committee, could be taken into consideration when nominating a new representative, subject to the availability of such expertise to the relevant competent authority in your country: • Paediatric psychiatry • Paediatric cardiology • Non-clinical development of medicinal products, including expertise in juvenile animal studies to support neonatal and paediatric studies • Biostatistics • Paediatric neurology • Paediatric nephrology/urology • Paediatric radiology/imaging • Gene therapy • Medical genetics − NCA staff member or Academic An overview of the current composition of the Committee and the expertise of its members is attached for your information. Please address the nomination to my attention at [email protected] (with copy to [email protected]), indicating full contact details for the nominee and the start date of the mandate, together with any additional information you believe may assist this nomination. In case you already provided me with your nomination, I kindly ask you to disregard this correspondence. Yours faithfully, Digitally signed by Emer Cooke Emer Cooke Date: 2026.06.08 10:30:32 +02'00' Emer Cooke Executive Director Encs: Annex B Current committee composition and expertise Page 2/2 Saatja: "Webdesktop" <[email protected]> Saaja: "Ravimiamet" <[email protected]>, "Info - SOM" <[email protected]>, "Elen Ohov - SOM" <[email protected]> Teema: [Webdesktop: Incoming document] Esindajate nimetamine Euroopa Ravimiameti pediaatriakomiteesse (PDCO) Kuupäev: 2026-06-10 09:15 Tere! Edastan Euroope Ravimiameti kirja. Vastama peab esinduse kaudu. Palun saatke info [email protected], koopiasse [email protected]. EV AEEL juures reg. number: 14-4/505 Reg. kuupäev: 10.06.2026 Sisu: Nomination of representatives in the Paediatric Committee (PDCO) of the European Medicines Agency / Esindajate nimetamine Euroopa Ravimiameti pediaatriakomiteesse (PDCO) -- Heade soovidega Tiiu Noobel sekretär, EV alaline esindus EL juures +32 2227 4337